Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Aptevo Therapeutics (APVO) Return on Capital Employed (2016 - 2025)

Aptevo Therapeutics (APVO) has disclosed Return on Capital Employed for 10 consecutive years, with 1.7% as the latest value for Q3 2025.

  • Quarterly Return on Capital Employed rose 99.0% to 1.7% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 1.7% through Sep 2025, up 99.0% year-over-year, with the annual reading at 1.76% for FY2024, 46.0% down from the prior year.
  • Return on Capital Employed hit 1.7% in Q3 2025 for Aptevo Therapeutics, up from 3.43% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.63% in Q2 2022 to a low of 3.67% in Q1 2025.
  • Historically, Return on Capital Employed has averaged 1.59% across 5 years, with a median of 1.25% in 2023.
  • Biggest five-year swings in Return on Capital Employed: surged 162bps in 2021 and later crashed -178bps in 2025.
  • Year by year, Return on Capital Employed stood at 0.84% in 2021, then plummeted by -41bps to 1.18% in 2022, then crashed by -30bps to 1.54% in 2023, then tumbled by -74bps to 2.69% in 2024, then skyrocketed by 37bps to 1.7% in 2025.
  • Business Quant data shows Return on Capital Employed for APVO at 1.7% in Q3 2025, 3.43% in Q2 2025, and 3.67% in Q1 2025.